Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production
about
T cell recognition of weak ligands: roles of signaling, receptor number, and affinityAntigen-based immunotherapy for autoimmune disease: current statusGlatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein.Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis.The role of TNFalpha and lymphotoxin in demyelinating disease.Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradationPeptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading.Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blockingActive immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injuryPeptide-based therapeutic vaccines for allergic and autoimmune diseases.Immune modulating peptides for the treatment and suppression of multiple sclerosis.Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update.Antigen-specific inhibition of CD4(+) T-cell responses to β-lactoglobulin by its single amino acid-substituted mutant form through T-cell receptor antagonism.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Endogenous altered peptide ligands can affect peripheral T cell responses.Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitisOptic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice.Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processingA T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens.Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet.Effects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisAmelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanismsThe multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease.Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.Restimulation-induced cell death: new medical and research perspectives.Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen.Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide.Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis.
P2860
Q24626152-AFC88CF8-6BEA-437F-9D5C-E2AC879C26F7Q26852915-43819E1D-5F7B-4C0E-BB04-DF552E6C574AQ33180102-405B89BC-DC38-4EB0-BCB1-2D20FAFA24D9Q33713319-3AE3FCA7-B87A-4427-A57D-5238BCEF33FEQ33753318-D420251A-AE5B-424C-9817-266384E966E1Q33753656-E4C94792-275D-4832-97CD-000CDC812FBFQ33782397-090C4223-896D-4E90-A000-D2C41A344C8BQ33793002-F92FC978-2F38-4641-BA37-319705007F97Q33819182-2CF07E28-F7F0-4BB9-B6A9-DB0834BCCA9AQ33838467-A206C0C1-AE0A-4E02-9D66-BA4DAB2CB9DBQ34307160-E521DB8C-A175-4D72-9F78-1D1B2FCD6559Q34380578-E2827AFA-6B75-4B73-8290-1D7839AE32B6Q34567730-E4410E53-20C4-4ADB-A913-C4E615FCCBE7Q34792611-203D0007-45F2-49A7-AC91-ED99510E9F06Q34795755-68DB73FC-393C-472A-8DDA-A37C50FA1D5BQ34830749-E1004DEF-40E2-4A0F-96EC-B9990EC277E5Q35121911-78C246F7-B224-4605-BCBD-EF28DA3A9353Q36090197-1C6733AD-E174-41A2-A747-8DCD13C6CDCEQ36151968-36CF33B7-43C4-452A-BDA3-8B992434EA7EQ36179710-C96B04EE-F441-45F5-99D7-EE930D3AC383Q36304701-D4FEF8CB-1A7D-4FFE-A95D-FB527EA64582Q36327377-0CDDDAE9-0809-4E00-A344-81BD14257941Q36366390-55808F95-855B-40BB-88F7-24A4C63D55ACQ36368042-760986C5-975A-403E-AB2B-FE29F33AADC0Q36370956-A44AB8F7-E482-4C1B-9811-139E64451C5DQ36376784-9BB9A241-D2D4-4530-B864-2C7D4409FCDDQ36376999-A5FE5AFF-3D22-4D4E-B11F-5D2A6F25A3E4Q36562710-ACD188F6-09A1-4240-AB39-64487DFB99CAQ36963194-AAB2A156-997E-480A-BF14-C1CA9EBBC933Q37261686-BAA3BE23-7A5E-4F5A-96DD-CFC251FCD9F7Q37415917-3044BC1A-C405-4EDB-A987-AE0F5CCE65F3Q37760665-164A54A4-6A53-4701-8617-DA47CF3B515AQ38207555-61DBE236-DD41-433A-880D-E20B37F632BFQ38477340-B3D58B63-A567-470D-905D-BB574F9A27D2Q39277444-7AC173D0-F5BA-4AE4-A336-6170D2E41840Q40418904-BF2234AF-E237-4D7B-A058-C5C27E119DF3Q40862395-60114D0E-6823-48A1-A618-57C7D467DE68Q41167186-B3F79E8F-D65E-451A-8C25-CA6C702CED9AQ41201845-938040EF-A374-4013-971C-38F1657435FCQ42063824-9CCE8238-F823-4343-BE03-3A27760A53AE
P2860
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Reversal of experimental autoi ...... crosis factor alpha production
@ast
Reversal of experimental autoi ...... crosis factor alpha production
@en
type
label
Reversal of experimental autoi ...... crosis factor alpha production
@ast
Reversal of experimental autoi ...... crosis factor alpha production
@en
prefLabel
Reversal of experimental autoi ...... crosis factor alpha production
@ast
Reversal of experimental autoi ...... crosis factor alpha production
@en
P2093
P2860
P356
P1476
Reversal of experimental autoi ...... crosis factor alpha production
@en
P2093
P2860
P304
P356
10.1084/JEM.180.6.2227
P407
P577
1994-12-01T00:00:00Z